Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Blood Studies for Cardiovascular System I: Cardiac Biomarkers01:20

Blood Studies for Cardiovascular System I: Cardiac Biomarkers

746
Cardiac biomarkers are enzymes, proteins, and hormones released into the blood when cardiac cells are injured. They are powerful tools for triaging.
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
746
Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers01:19

Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers

511
Cardiac biomarkers are critical in diagnosing, prognosing, and managing cardiovascular diseases. Routine measurement of specific biomarkers such as B-type natriuretic peptide (BNP), C-reactive protein (CRP), and homocysteine (Hcy) is common practice in clinical settings to evaluate heart function and predict cardiovascular events.
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...
511

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same journal

Deep learning-based MRI analysis reveals Lewy body co-pathology accelerates brain aging in Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Changes in body composition in genetic C9orf72 carriers: The role of the hypothalamus and thalamus.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Age predicts Alzheimer's in Down syndrome better than MRI, plasma, or cognition.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Structural MRI across lifespan reveals differential thalamic trajectories in Down syndrome.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Early Alzheimer´s disease blood biomarkers are associated with a higher risk for postoperative long-term cognitive decline: Insights from the FINDERI study.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same journal

Heterogeneous associations of cumulative heat exposure with cognitive decline among older Japanese adults.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K

Biomarkers.

Anjali Rose Friedman1

  • 1Adams State University, Alamosa, CO, USA.

Alzheimer'S & Dementia : the Journal of the Alzheimer'S Association
|December 24, 2025
PubMed
Summary

This study explores using Psilocybe cubensis and Hericium erinaceus mushrooms to potentially treat Alzheimer's disease symptoms. Findings suggest these natural compounds may reduce neuro-inflammation and improve cognitive function.

Area of Science:

  • Neuroscience
  • Pharmacology
  • Mycology

Background:

  • Recent research indicates neuroprotective effects of specific mushrooms.
  • Alzheimer's disease (AD) presents neurological and neuropsychological challenges.
  • Psilocybe cubensis and Hericium erinaceus show promise for mood and cognitive enhancement.

Purpose of the Study:

  • To investigate the potential of P. cubensis and H. erinaceus in mitigating AD symptoms.
  • To explore natural therapeutic avenues for Alzheimer's disease.
  • To hypothesize a novel treatment approach for AD using medicinal mushrooms.

Main Methods:

  • Oral supplementation with P. cubensis (1g-3.5g) and H. erinaceus extracts (hericenones, erinacines).
  • Monitoring AD patient mental health using the Beck Depression Inventory (BDI).

More Related Videos

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699

Related Experiment Videos

Last Updated: Jan 7, 2026

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies
07:20

Dried Blood Spot Collection of Health Biomarkers to Maximize Participation in Population Studies

Published on: January 28, 2014

37.1K
Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

7.9K
Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans
08:14

Ecotoxicological Methodologies to Evaluate Biomarkers at Different Scales in Neotropical Anurans

Published on: April 28, 2023

699
  • Assessing neuro-inflammation via CT/MRI and evaluating neurotrophic factor mimicry.

    • Main Results:

    • P. cubensis may boost microglial cells and IDE, aiding beta-amyloid plaque breakdown.
    • Psilocybin's interaction with the 5HT-2A pathway could alleviate mood disorders in AD.
    • H. erinaceus extracts may reduce tau/beta-amyloid, reverse myelin degradation, and promote hippocampal cell proliferation.

    Conclusions:

    • P. cubensis shows significant potential for mental and brain health applications.
    • Increased research funding and leniency for P. cubensis studies are recommended.
    • Novel therapeutic strategies for AD utilizing natural compounds warrant further investigation.